EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR-positive/HER2-negative breast cancer

L Licata, M Mariani, A Chiavassa, A H Partridge, C Zanibelli, K Jhaveri, K Kalinsky, F Patanè, C Criscitiello, M Lambertini, H S Rugo, M M Naldini und 4 weitere

Annals of Oncology · 2026-09

DOI: 10.1016/j.annonc.2026.09.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Oncology, 2026-09. Verfasst von L Licata und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. Die Arbeit nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AIRC Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer represent a clinically distinct population, characterized by more aggressive tumor biology, unique survivorship concerns, and complex treatment decision making. Although evidence from dedicated trials and subgroup analyses is available, management remains challenging because data are heterogeneous, evolving, and often extrapolated from broader populations that include predominantly postmenopausal women. Adjuvant endocrine therapy (ET), with the addition of cyclin-dependent kinase 4/6 inhibitors in selected higher-risk patients, remains the cornerstone of treatment; however, major uncertainties persist regarding the optimal use of ovarian function suppression, the interpretation of genomic assays to inform chemotherapy decisions, the selection of candidates for extended ET, and the management of adherence, treatment-related toxicities, pregnancy-related issues, and survivorship concerns. In this review, we synthesize current evidence across these domains and propose a pragmatic clinical framework to support individualized treatment strategies and optimize care for this population in the contemporary therapeutic landscape.

Schlagwörter

Stichwörter der Autor:innen

HR-positive/HER2-negative early breast canceradjuvant therapypremenopausal womenuncertainties

Autor:innen und Institutionen

  • Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy; Yale School of Medicine, Yale Cancer Center, New…
  • Department of Medical Oncology, Santa Croce e Carle Hospital, Cuneo, Italy.
  • Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA.
  • Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Weill Cornell Medical Center, New York, USA.

Förderung

  • AIRC Foundation for Cancer Research

Zitieren

APA

Licata, L., Mariani, M., Chiavassa, A., Partridge, A. H., Zanibelli, C., Jhaveri, K., Kalinsky, K., Patanè, F., Criscitiello, C., Lambertini, M., Rugo, H. S., Naldini, M. M., Notini, G., Viale, G., Pusztai, L., & Bianchini, G. (2026). Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR-positive/HER2-negative breast cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2026.09.005

Vancouver

Licata L, Mariani M, Chiavassa A, Partridge AH, Zanibelli C, Jhaveri K, et al. Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR-positive/HER2-negative breast cancer. Annals of Oncology. 2026. doi:10.1016/j.annonc.2026.09.005

BibTeX
@article{Licata2026,
  author = {Licata, L and Mariani, M and Chiavassa, A and Partridge, A H and Zanibelli, C and Jhaveri, K and Kalinsky, K and Patanè, F and Criscitiello, C and Lambertini, M and Rugo, H S and Naldini, M M and Notini, G and Viale, G and Pusztai, L and Bianchini, G},
  title = {Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR-positive/HER2-negative breast cancer},
  journal = {Annals of Oncology},
  year = {2026},
  doi = {10.1016/j.annonc.2026.09.005}
}
Kostenlos starten →